S
S

Siemens

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Siemens Acquires Technology Company Buntplanet

BRIEF-Siemens Acquires Technology Company Buntplanet Dec 5 (Reuters) - Siemens AG SIEGn.DE : SIEMENS AG - SIEMENS ACQUIRES BUNTPLANET TO STRENGTHEN ITS ARTIFICIAL INTELLIGENCE PORTFOLIO IN THE WATER SECTOR Source text for Eikon: [ID:] Further company coverage: [SIEGn.DE] (Gdansk Newsroom)
S

Siemens And Intel To Collaborate On Advanced Semiconductor Manufacturing

BRIEF-Siemens And Intel To Collaborate On Advanced Semiconductor Manufacturing Dec 4 (Reuters) - SIEMENS AG SIEGn.DE : SIEMENS AND INTEL TO COLLABORATE ON ADVANCED SEMICONDUCTOR MANUFACTURING INTEL AND SIEMENS WILL LEVERAGE THEIR RESPECTIVE PORTFOLIOS OF CUTTING EDGE IOT SOLUTIONS, ALONG WITH SIEMENS AUTOMATION SOLUTIONS TO ENHANCE SEMICONDUCTOR MANUFACTURING EFFICIENCY AND SUSTAINABILITY SIEMENS AND INTEL HAVE SIGNED A MEMORANDUM OF UNDERSTANDING (MOU) TO COLLABORATE ON DRIVING DIGITALIZATION A
I
S

Intel, Siemens to collaborate on improving manufacturing, energy efficiency

Intel, Siemens to collaborate on improving manufacturing, energy efficiency By Max A. Cherney Dec 4 (Reuters) - Intel INTC.O and Siemens SIEGn.DE on Monday announced a three-year deal to collaborate on improving factory efficiency and automation with a special focus on improving energy efficiency and sustainability. "Intel has big plans with our expansions, but we want to make sure that we do that with the utmost focus on efficiencies of natural resources and our commitments to the net zero," In
I
S

UK's CMA Says Siemens/ Heliox Merger Does Not Qualify For Probe

BRIEF-UK's CMA Says Siemens/ Heliox Merger Does Not Qualify For Probe Dec 1 (Reuters) - UK's CMA: UK'S CMA SAYS SIEMENS/HELIOX MERGER DOES NOT QUALIFY FOR INVESTIGATION UNDER MERGER PROVISIONS Source text for Eikon: ID:nRSA1101Va
S

'Convalescence is over': Jefferies sees upbeat 2024 for European MedTech

BUZZ-'Convalescence is over': Jefferies sees upbeat 2024 for European MedTech ** Jefferies initiates coverage of eleven European medical technology firms, with seven "buy" ratings, seeing a better 2024 after a downbeat market performance over the past two years ** It says hopes for normalized inflation and stabilizing rates make MedTech attractive
C
E
P
S
S
S
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.